RYTM
Rhythm Pharmaceuticals, Inc. Common Stock
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
110.00
▲ 1.08 (0.99%)
MARKET · —
Price
Open
108.91
Prev close
108.92
Day high
112.59
Day low
106.58
Volume
506.21K
Market cap
$7.57B
P/E (TTM)
—
52W range
74.50 – 122.20
Trailing performance
Returnvs SPY
1W
-4.75%
-3.4%
1M
+7.15%
+3.4%
3M
+21.96%
+18.9%
6M
+10.24%
-0.8%
YTD
+2.77%
-9.5%
1Y
+11.45%
-8.5%
3Y
+332.05%
+257.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$7.57B
Enterprise value$7.47B
Revenue (TTM)$239.92M
Gross profit$213.53M
EBITDA$-199.55M
Net income$-210.22M
EPS (TTM)$-3.12
Free cash flow$-130.59M
Total cash$330.90M
Total debt$109.78M
Book value / share$1.50
Shares outstanding68.85M
Float56.03M
Short % of float13.83%
Dividend yield—
Beta (5Y)1.97
Valuation & profitability ratios
Trailing P/E—
Forward P/E-179.91
PEG ratio—
Price / sales—
Price / book73.53
EV / revenue31.12
EV / EBITDA-37.42
Gross margin89.00%
Operating margin-68.14%
Profit margin-85.59%
Return on equity-117.05%
Return on assets-30.96%
Debt / equity50.52
Current ratio3.45
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $189.76M | $130.13M | $77.43M | $23.64M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$201.92M | -$264.57M | -$184.68M | -$181.12M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$201.92M | -$264.57M | -$184.68M | -$181.12M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.83 | -0.73 | +12.4% |
| Mar 2026 | -0.86 | -0.83 | +3.6% |
| Dec 2025 | -0.78 | -0.73 | +6.4% |
| Sep 2025 | -0.73 | -0.82 | -11.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.75 | 11 | $83.87M | +63.5% |
| Next quarter | -0.73 | 11 | $97.93M | +71.0% |
| Current year | -3.07 | 11 | $313.60M | +65.3% |
| Next year | -0.61 | 11 | $561.13M | +78.9% |
Analyst targets & ownership
Mean target$141.53
High target$160.00
Low target$105.00
Implied upside28.67%
Analyst count15
ConsensusSTRONG BUY
Strong buy / Buy5 / 10
Hold1
Sell / Strong sell0 / 0
Held by insiders0.71%
Held by institutions114.68%
Institutions holding425
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+6.40K
Net buying
Buy transactions
16
199.33K shares
Sell transactions
7
192.93K shares
Net transactions
+23
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
487.47K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 13, 26 | LEE JENNIFER KAYDEN Officer |
SELL | 75.83K | $8.90M | Direct |
| Aug 13, 26 | SHULMAN JOSEPH J Chief Technology Officer |
SELL | 5.08K | $608.21K | Direct |
| Aug 13, 26 | GARFIELD ALASTAIR PH.D. Officer |
SELL | 7.76K | $912.70K | Direct |
| Aug 13, 26 | SHULMAN JOSEPH J Chief Technology Officer |
CONVERSION | 2.02K | $13.76K | Direct |
| Aug 13, 26 | LEE JENNIFER KAYDEN Officer |
CONVERSION | 56.60K | $997.04K | Direct |
| Aug 12, 26 | MAZABRAUD YANN Officer |
SELL | 57.00K | $6.62M | Direct |
| Aug 12, 26 | MAZABRAUD YANN Officer |
CONVERSION | 46.63K | $317.05K | Direct |
| Jul 1, 26 | GARFIELD ALASTAIR PH.D. Officer |
— | 4.45K | — | Direct |
| Jun 23, 26 | GOOD JENNIFER L Director |
— | 4.71K | — | Direct |
| Jun 23, 26 | MCGIRR DAVID W J Director |
— | 4.71K | — | Direct |
| Jun 23, 26 | JEAN CHRISTOPHE R Director |
— | 4.71K | — | Direct |
| Jun 23, 26 | ARBUCKLE STUART A Director |
— | 4.71K | — | Direct |
| Jun 23, 26 | TETRAULT LYNN A. Director |
— | 4.71K | — | Direct |
| Jun 22, 26 | TETRAULT LYNN A. Director |
SELL | 37.00K | $3.71M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CRAMER PAMELA J. |
Officer | 29.38K | Conversion of Exercise of derivative security |
GOOD JENNIFER L |
Director | 11.71K | Conversion of Exercise of derivative security |
JEAN CHRISTOPHE R |
Director | 11.71K | Conversion of Exercise of derivative security |
MATHERS EDWARD T. |
Director | 12.77K | Conversion of Exercise of derivative security |
MAZABRAUD YANN |
Officer | 55.66K | Sale |
MCGIRR DAVID W J |
Director | 11.71K | Conversion of Exercise of derivative security |
MEEKER DAVID P |
Chief Executive Officer | 239.02K | Conversion of Exercise of derivative security |
SHULMAN JOSEPH J |
Chief Technology Officer | 15.91K | Sale |
SMITH HUNTER C |
Chief Financial Officer | 119.61K | Conversion of Exercise of derivative security |
TETRAULT LYNN A. |
Director | 11.71K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
114.28
-3.74% from price
SMA 20
110.77
-0.70% from price
SMA 50
107.33
+2.49% from price
SMA 100
97.57
+12.74% from price
SMA 200
99.16
+10.93% from price
EMA 12
112.43
-2.16% from price
EMA 26
110.42
-0.38% from price
EMA 50
106.72
+3.07% from price
RSI (14)
49.6
Neutral
MACD (12,26,9)
2.01
Hist -0.46
ATR (14)
5.12
4.66% of price
Realised vol 30D
41.8%
Annualised
Bollinger upper
120.90
20, 2σ
Bollinger lower
100.65
20, 2σ
50 / 200 cross
Golden
107.33 vs 99.16
Trend bias
Above 200
+10.93%
Risk profile
Beta vs SPY
0.98
Less volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
41.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-35.5%
Peak to trough
Max drawdown 5Y
-77.6%
Peak to trough
ATR 14
5.12
4.66% of price
Beta (reported)
1.97
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.37
Call-heavy session
Put / call open interest
0.03
Positioning, not flow
Max pain
110.00
0.0% from spot
ATM implied vol
63.4%
Nearest strike to spot
Skew (10% OTM)
+8.4%
Puts bid over calls
Call volume
19
Contracts, this expiry
Put volume
7
Contracts, this expiry
Heaviest call OI
115.00
320 contracts
Heaviest put OI
100.00
4 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
GlobeNewswire · 5d ago
Rhythm Pharmaceuticals Insider Sold Shares Worth $6,620,575, According to a Recent SEC Filing
MT Newswires · 5d ago
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
MarketBeat · 5d ago
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
Rhythm Pharmaceuticals' Imcivree Receives Expanded Marketing Authorization in UK
MT Newswires · 11d ago
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
GlobeNewswire · 11d ago
RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating
MT Newswires · 17d ago
Rhythm Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.